Tuesday, 16 Oct 2018

You are here

FIELD Study: Fenofibrate Reduces Uric Acid and Gout Risk

Lancet reports the results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study - where fenofibrate was shown to reduce uric acid by 20%, gout events by nearly 50% and may be useful in preventing gout in diabetes. 

In the study, 9795 adults (age 50–75 years) with type 2 diabetes were randomized to receive fenofibrate 200 mg per day or placebo and followed for up to 5 years.

In the fenofibrate group, serum uric acid levels fell by 20·2% during a 6-week active fenofibrate run-in period (a reduction of 0·06 mmol/L or 1 mg/dL) and remained −20·1% (p<0·0001) lower for those re-measured at 1 year.

First new gout events were seen in 3% of placebo and 2% of fenofibrate patients during 5 years of follow-up (HR 0·54, 95% CI 0·41–0·70; p<0·0001).

Cumulative gout attacks were higher In the placebo group based on baseline uric acid concentration (7·7% or 13.9% if higher than 0·36 mmol/L or 0·42 mmol/L) versus only 3·4% or 5·7% in the fenofibrate group.

Analyzing all gout events, fenofibrate reduced the risk of gout events by 52% (HR 0·48, 95% CI 0·37–0·60; p<0·0001) compared with placebo.

Previous small and short term studies have shown fenofibrate to lower uric acid and reduces gout attacks.  The current study shows a sustained 20% reduction in uric acid levels that translates to fewer cases of incident gout in those with diabetes.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Allopurinol Shown to be Renal Protective

Neogi and colleagues have shown that standard doses of allopurinol (300 mg/day) were associated with a 13% lower risk of renal function deterioration in chronic gout patients - thus, allopurinol does not appear to impair renal function over time.

Quarterly Canakinumab Reduces Gout Risk Without Affecting Uric Acid

The Annals of Internal Medicine reports that interleukin-1 (IL-1) inhibitor treatment is associated with a reduced risk of gout attacks - such are the findings of an anlysis of the CANTOS study previously reported at the Annual ACR 2017 meeting in Washington, DC. 

Usual Allopurinol Doses Insufficient in CKD Patients

Uric acid (sUA) control may be a challenge in patients with chronic kidney disease (CKD). A cohort study shows that conventional dosing recommendations for allopurinol are unlikely to reach target serum sUA goals.

Sleep Apnea Raises Gout Risk

Patients with obstructive sleep apnea were at increased risk for incident gout, particularly in the first years after the sleep apnea diagnosis, U.K. researchers reported.

In a large retrospective cohort study, the adjusted hazard ratio for a new gout diagnosis among individuals with sleep apnea was 1.42 (95% CI 1.29-1.56), according to Milica Blagojevic-Bucknall, PhD, of Keele University in Keele, England, and colleagues.

Adherence to Gout Therapies Painfully Low

A retrospective study of the large UK Clinical Practice Research Datalink assessed patient compliance in gout and found that adherence to allopurinol is poor, especially among females and younger patients and those with fewer comorbidities.